Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders

• Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases

• Domain Therapeutics is eligible to receive upfront, milestone and royalty payments

Strasbourg, France, December 4, 2018 – Domain Therapeutics announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area. The collaboration combines the expertise of Domain Therapeutics, a French and Canadian biopharmaceutical company, in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications.

Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable a comprehensive characterization of small molecule GPCR binders for the screening and characterization of potential lead compounds. In addition, Domain brings on board its extensive network of leading GPCR experts to provide additional knowledge and insight to the discovery phase (Prof Brigitte Kieffer (Douglas Institute – Montreal, Canada) and Prof Michel Bouvier (IRIC Institute – Montreal, Canada).

Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details are not disclosed.

“We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts,” says Dr Bernd Sommer, Global Head, CNS Diseases Research. “We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”

“With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim,” says Pascal Neuville, CEO of Domain Therapeutics. “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets, and, coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”

Download the pdf